A chronological record of peer-reviewed Ipamorelin research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Ipamorelinworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Ghrelin Receptor Agonism. Primary indications investigated: Growth hormone release, Body composition, Sleep quality, Recovery.
Study demonstrating ipamorelin-induced GH elevation enhanced dermal collagen content and skin elasticity.
Trial demonstrating ipamorelin improved insulin sensitivity, lipid profile, and reduced inflammation.
Preclinical research showing ipamorelin augmented T-cell and B-cell immune responses.
Study showing ipamorelin-induced GH elevation increased serum and tissue IGF-1 production.
Preclinical study showing ipamorelin-induced GH elevation improved cognitive performance and memory consolidation.
Study demonstrating ipamorelin accelerated recovery of gut motility and feeding tolerance post-operatively.
Study showing ipamorelin enhanced cardiac function and improved exercise performance.
Trial in GH-deficient patients demonstrating ipamorelin restored physiological GH pulsatility.
Long-term study showing ipamorelin enhanced bone formation markers and improved bone mineral density.
Pulsatile secretion study demonstrating ipamorelin enhanced GH pulse frequency and amplitude.
Phase 2b trial demonstrating ipamorelin increased lean body mass and reduced adiposity.
Phase 2 trial of IV ipamorelin for postoperative GI recovery. Showed acceleration of bowel function return after abdominal surgery. Well-tolerated with favorable safety profile.
Extended safety study confirming ipamorelin maintained efficacy and safety over 12 months.
Preclinical studies elucidating ipamorelin mechanism as GH secretagogue distinct from ghrelin receptor agonism.
Comprehensive pharmacological characterization confirming ipamorelin selectivity across multiple species and dose ranges, with comparison to GHRP-6 and GHRP-2.
Phase 2 study demonstrating ipamorelin selective GH secretion without ACTH, cortisol, or prolactin elevation.
Foundational selectivity study in swine showing ipamorelin stimulated GH with efficacy equal to GHRP-6 but without elevating ACTH, cortisol, or prolactin — even at 200x effective dose.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Ipamorelin is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
PeptideMark indexes 33 studies on Ipamorelin: 4 human studies, 18 animal studies, 6 in-vitro, and 5 reviews. The current evidence level is L3 — emerging clinical evidence.
The earliest indexed peer-reviewed study on Ipamorelin in the PeptideMark library was published in 1998 (Journal of Endocrinology). Research activity has continued through 2007.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Ipamorelin has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.